Home

Agios Pharmaceuticals, Inc. - Common Stock (AGIO)

36.41
-0.37 (-1.01%)
NASDAQ · Last Trade: Sep 15th, 2:22 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or “the Company”) (NASDAQ: AGIO) for violations of the securities laws.
By Schall Law Firm · Via Business Wire · September 15, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · September 14, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   
By Pomerantz LLP · Via GlobeNewswire · September 10, 2025